Diabetes Self-Management Articles

These articles cover a wide range of subjects, from the most basic aspects of diabetes care to the nitty-gritty specifics.

Links not loading properly?

Some of our pages use Portable Document Format (PDF) files, which require Adobe Acrobat Reader. To download Acrobat Reader for free, visit www.adobe.com.

Sign up for our weekly e-mail newsletter and receive a FREE GIFT! Enter your e-mail below.

Learn more

Learn more about diabetes

Links to help you learn more about diabetes.

Ask a diabetes expert
Other diabetes resources
Browse article topics


DPP-4 Inhibitors

by Mark T. Marino, MD

Sitagliptin results in a low incidence of hypoglycemia, comparable to that of placebo, when tested as a stand-alone therapy. It is associated with a somewhat higher rate of hypoglycemia when used in combination with other drugs, especially with a sulfonylurea such as glipizide or glimepiride.

As mentioned earlier, DPP-4 was discovered through its association with the immune system, and some researchers thought that inhibiting it might impair the immune system. So far, data from clinical studies have not demonstrated a serious immunosuppresive effect. They do indicate, though, that sitagliptin increases the risk of upper respiratory infections and nasopharyngitis (inflammation of the nose and pharynx), found in 6.3% and 5.2% of study subjects, respectively, who took sitagliptin versus 3.3% and 3.4% for placebo.

The most worrying side effects are those reported since the drug came onto the market. These reactions seem to be allergic in nature and include anaphylaxis, a bodywide reaction that results in low blood pressure, and angioedema, a swelling of the tongue, face, and throat. Both of these may be life-threatening. The reactions have occurred anytime from immediately after taking the first dose until three months after starting the drug. There have also been reports of skin reactions, including a very severe type of drug reaction called Stevens–Johnson syndrome. Other diabetes drugs are not typically associated with Stevens–Johnson syndrome.

One more choice
DPP-4 inhibitors may be a useful addition to the treatment options for Type 2 diabetes. While the current DPP-4 inhibitors do not seem to have major, clearcut advantages over other therapies, they may be a reasonable alternative for people who cannot take certain other drugs. They may also be used with metformin when blood glucose control is not ideal. Whether these drugs could be used to preserve or improve pancreatic beta-cell function, as well, will be determined through further clinical trials. As options for treating Type 2 diabetes expand, new drugs, including DPP-4 inhibitors, help make it possible for more people to follow an effective, individualized plan for their diabetes.

Page    1    2    3    4    Show All    



More articles on Type 2 Diabetes
More articles on Oral Medicines
More articles on Diabetes Research



Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information provided on this Web site should not be construed as medical instruction. Consult appropriate health-care professionals before taking action based on this information.



Tools of the Trade 2013
Many of 2013's new diabetes tools are redesigns of earlier products: A pen needle, a continuous... Article

A month's supply costs you about the same as a Starbucks latte. It's one of the oldest drugs... Article

Updated Treatment Guidelines for Type 2 Diabetes
In 2012, the American Diabetes Association (ADA), along with the European Association for the... Article

I'm feeling fine. Do I still have to keep an eye on my blood glucose levels? Get tip